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Introduction: The ischemic time serves as the most important parameter for 
treatment choice in patients with ST-elevation myocardial infarction (STEMI). The 
current study aimed at comparing the short- and long-term follow-up of elderly 
patients with STEMI undergoing primary angioplasty (PCI) or thrombolytic therapy. 
Methods: The current cross sectional study was conducted on all patients aged > 65 
years, admitted to the emergency department of Imam Hossein Hospital, Tehran, Iran 
from January 2014 to July 2016, diagnosed with STEMI. The demographics, medical 
history, family history, and mediation history were recorded for all patients. Patients 
received PCI or thrombolytic therapy based on the ischemic time and the treatment 
outcome and the following events were recorded. Patients were contacted after six 
months and data of their death or used treatments were recorded. All data were 
compared between the groups. 
Results: Of all patients, 38 subjects received thrombolytic therapy and 62 PCI. There 
was no significant difference between the groups in terms of mean age and gender (P 
= 0.5 and 0.1, respectively). The frequency of positive medical history and smoking did 
not differ between the groups. There was no difference in the mean values of vital signs 
or serum parameters, mean ischemic time, left ventricular ejection fraction (LVEF), 
frequency of pulmonary emboli, cardiogenic shock, the involved vessel, and post-
treatment complications between the groups (P > 0.05). Of the 14 cases that died after 
six months, five were in the thrombolytic therapy group and nine in the PCI group (P 
= 0.8). Mean hospital stay was not different between the groups (P = 0.5). 
Conclusions: The results of the present study on two groups with similar 
demographics showed no significant difference between the groups in terms of the 
short- and long-term follow-up of PCI and thrombolytic therapy. The results indicated 
the appropriateness of treatment choice based on ischemic time and the available 
methods. 
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INTRODUCTION
Cardiovascular diseases (CVDs) are the leading cause of 
mortality worldwide [1], responsible for one in every 2-
3 deaths (one death each 40 seconds) in the United 
States, causing death of more than 2200 Americans each 
day [2]. There is a significant difference between the 
low- and high-income countries in CVD-associated 
International Journal of Cardiovascular Practice  Kazemi et al 
11 
deaths and the growing incidence of coronary artery 
disease (CAD) [3]. Asia accounts for the greatest 
mortality and morbidity caused by ischemic heart 
disease (IHD) and ischemic stroke in the world [4].In 
Iran, the annual IHD mortality rate is estimated as 14 
per 1000 population over 40 years old with about 3 
million individuals that need outpatient care [5]. 
The timely diagnosis is the key factor for the treatment 
success of acute myocardial infarction (MI), and 
electrocardiographic measurements, identifying ST-
elevation myocardial infarction (STEMI), and serum 
parameters such as troponin and creatinine kinase 
(CK)-MB are suggested for early diagnosis [6]. Based 
on the ischemic time, the American College of 
Cardiology (ACC)/American Heart Association 
(AHA) suggested the choice of treatment [7]. An 
effective treatment to resolve the blocked cardiac vessel 
and restoring the blood perfusions is percutaneous 
coronary intervention (PCI), as well as coronary artery 
bypass graft (CABG) [8].Hence, several studies 
suggested the priority of PCI over thrombolytic therapy 
[9-11], while evidence suggest that the treatment choice 
and mortality rates of STEMI may depend on several 
factors including patients’ characteristics [12]. 
Therefore, the results cannot be generalized to other 
populations. 
Since patients with CAD have significantly lower quality 
of life in Iran [13], it is essential to study the short- and 
long-term follow-up for post-treatment morbidities to 
provide a better perspective towards the efficacy and 
priority of treatments [14]. Therefore, the current study 
aimed at comparing the short- and long-term follow-up 
of patients with STEMI undergoing PCI or 
thrombolytic therapy, selected based on ischemic time. 
Methods 
Study Design 
The current study was conducted on all patients aged > 
65 years referring to the emergency department (ED) of 
Imam Hossein Hospital, Tehran, Iran from January 
2014 to July 2016, diagnosed with STEMI. Diagnosis of 
STEMI was based on ACC/AHA guidelines; the 
presence of typical angina for 30 minutes to 12 hours 
with electrocardiographic changes [7]. Patients 
receiving thrombolytic therapy in another center and 
referred to the current study department for rescue PCI 
were excluded from the study. 
The participants’ information was collected by asking 
their attendants and recording in the study checklist by 
the research assistant; the collected data included 
demographic information, medical history, and drug 
history. Before catheterization or thrombolytic therapy, 
a blood sample was taken from all participants and 
immediately sent to the hospital’s laboratory to measure 
the serum parameters. 
The ischemic time was recorded for all patients based on 
the attendants’ reports, and accordingly, the patient was 
candidate to receive PCI or thrombolytic therapy, based 
on ACC/AHA guidelines and the available method on 
the arrival of the patient [7]. The reteplase thrombolytic 
agent was used in the study. If the symptoms of heart 
failure or cardiogenic shock were observed in patients 
receiving thrombolytic or not resolving ST-elevation 
after 60 minutes, the patient was candidate for rescue 
PCI. Echocardiography was performed one day after 
revascularization to evaluate the left ventricular ejection 
fraction (LVEF). 
Six months after discharge, the patient was contacted by 
telephone calls to check if he/she was alive, being re-
admitted, or required angiography, revascularization, or 
any additional treatments. Also, the complications 
(gastrointestinal bleeding, stroke, and MI) were asked 
and recorded in the study checklist. 
The study protocol was approved by the Ethics 
Committee of Shahid Beheshti University of Medical 
Sciences. Before enrolling the patients in the study, the 
design and objectives of the study were explained to 
them or their attendants and written informed consent 
was obtained. The participants were assured about the 
confidentiality of their information; data analysis and 
reports were performed anonymously. 
Statistical Analysis 
Data were transferred into the computer and analyzed 
with SPSS version 21.0 (IBM Corp. 2012. Armonk, NY: 
IBM Corp). Results of quantitative variables were 
expressed as mean ± standard deviation (SD) and those 
of the qualitative variables as frequency (percentage). 
The Kolmogorov-Smirnov test was employed to assess 
the normal distribution of data. Continuous variables 
were compared using t test or the Mann-Whitney U test 
when the data had non-normal distribution or the 
assumption of equal variances was violated across the 
study groups. Categorical variables were, on the other 
hand, compared using chi-square test. The association 
between the variables was tested by Pearson correlation 
coefficient. For all tests, P-value < 0.05 was considered 
statistically significant. 
Results 
Data of 100 patients were analyzed. Most participants 
(61%) were male. Mean ± standard deviation (SD) of 
patients’ age was 72.68 ± 6.23 years (range 65 to 94). Of 
all patients, 38 cases received thrombolytic therapy and 
62 PCI. Mean age of patients was not different between 
the groups (72.38 ± 6.17 years in PCI group vs. 73.15 ± 
6.46 years in thrombolytic therapy group) (P = 0.5). 
Thirty four patients in PCI group and 27 in 
thrombolytic therapy group were male (P = 0.1). 
Median ischemic time was 2.5 hours. 
The frequency of positive medical history and 
medications taken by patients did not differ between the 
groups, except for angiotensin-converting-enzyme 
inhibitor, which its frequency was significantly higher in 
the PCI group (Table 1).Only two patients (2%) had a 
positive family history of cardiac diseases; one in each 
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group (P = 0.7).Of all patients, 23 were smokers and five 
reported opium abuse; the frequencies of smoking and 
substance abuse were not different between the groups 
(P = 0.5 and 0.9, respectively). 
There was no significant difference in the mean values of 
vital signs or serum parameters between the groups (P > 
0.05) (Table 2).There was no significant difference 
between the groups in terms of ischemic time, LVEF, 
frequency of pulmonary emboli, cardiogenic shock, and 
vessel involvement (P > 0.05) (Table 3). 
 
Table 1. Comparing the Frequency of Positive Medical History and Medications Used by Patients between the Study Groups 
 Total, No. = 100 PCI group, No. = 62 Thrombolytic group, No. = 38 P value 
Past medical history 
Dyslipidemia  24 (24) 16 (25.8) 8 (21) 0.58 
Hypertension  62 (62) 41 (66.1) 21 (55.2) 0.27 
Diabetes mellitus 38 (38) 27 (43.5) 11 (28.9) 0.14 
Renal failure 3 (3) 1 (1.6) 2 (5.2) 0.29 
Dialysis  1 (1) 1 (1.6) 0 (0) 0.43 
Peripheral artery disease 0 (0) 0 (0) 0 (0) – 
Coronary artery disease 20 (20) 14 (22.5) 6 (15.7) 0.41 
Cerebrovascular ischemia 6 (6) 3 (4.8) 3 (7.8) 0.53 
Previous myocardial infarction 9 (9) 7 (11.2) 2 (5.2) 0.30 
Heart failure 0 (0) 0 (0) 0 (0) – 
Previous PCI 9 (9) 5 (8) 4 (10.5) 0.67 
Previous CABG 4 (4) 2 (3.2) 2 (5.2) 0.61 
Medications used 
Aspirin  30 (30) 18 (29) 12 (31.5) 0.78 
Clopidogrel  7 (7) 3 (4.8) 4 (10.5) 0.29 
Beta–blocker 22 (22) 14 (22.5) 8 (21) 0.85 
Statins  13 (13) 7 (11.2) 6 (15.7) 0.51 
ACEi 27 (27) 21 (33.8) 6 (15.7) 0.04 
Data in table are presented as No. (%). 
PCI: Percutaneous coronary intervention, CABG: Coronary artery bypass grafting, ACEi: Angiotensin-converting-enzyme inhibitor. 
 
Table 2. Comparing the Vital Signs of Patients and Serum Parameters between the Two Study Groups 
 Total, No. = 100 PCI group, No. = 62 Thrombolytic group, No. = 38 P value 
Systolic blood pressure, mmHg 127.35 ± 35.27 126.38 ± 35.66 128.88 ± 35.09 0.7 
Diastolic blood pressure, mmHg 79.56 ± 14.67 78.60 ± 15.38 81.16 ± 13.50 0.4 
Heart rate, beat/minute 80.70 ± 15.35 81.53 ± 16.00 79.42 ± 14.43 0.5 
Oxygen saturation, percent 93.66 ± 4.52 93.48 ± 5.04 93.92 ± 3.71 0.7 
White blood cell count, u/L 9.36x109 ± 3.31x109 9.17x109 ± 3.55x109 9.66x109 ± 2.91x109 0.4 
Hemoglobin, mg/dl 12.93 ± 1.67 12.69 ± 1.57 13.33 ± 1.78178 0.07 
Platelet count 225042.10 ± 66388.75 227474.57 ± 53102.16 221055.55 ± 84486.66 0.6 
Creatinine, mg/dl 1.21 ± 0.58 1.23 ± 0.67 1.20 ± 0.42 0.7 
Cholesterol, mg/dl 164.73 ± 38.15 165.15 ± 42.48 164.22 ± 32.60 0.9 
Low density protein, mg/dl 97.42 ± 28.70 97.30 ± 32.26 97.60 ± 23.90 0.9 
High density protein, mg/dl 39.45 ± 8.76 39.22 ± 8.67 39.72 ± 8.99 0.8 
Triglyceride, mg/dl 117.22 ± 73.08 111.37 ± 65.01 124.30 ± 82.30 0.4 
Fasting blood sugar, mg/dl 175.35 ± 101.64 190.89 ± 103.21 149.89 ± 94.97 0.05 
Data in table are presented as Mean ± SD 
 
Table 3. Comparing the Cardiac Parameters of Patients between the Two Study Groups 
Variable  Total, No. = 100 PCI group, No. = 62 Thrombolytic group, No. = 38 P value 
Ischemic time, hours 5.21 ± 7.60 4.95 ± 6.91 5.57 ± 8.52 0.7 
Left ventricular ejection fraction, % 40.98 ± 11.65 41.66 ± 11.92 40.34 ± 11.56 0.6 
Positive pulmonary emboli 4 (4%) 2 (3.2%) 2 (5.2%) 0.6 
Positive cardiogenic shock 14 (14%) 11 (17.7%) 3 (7.8%) 0.1 
Primary CK-MB, u/L 59.03 ± 72.54 66.20 ± 85.24 48.19 ± 46.33 0.2 
Maximum CK-MB, u/L 192.36 ± 183.31 184.82 ± 187.11 202.10 ± 180.87 0.6 
First troponin, ng/L 3.21 ± 7.08 3.61 ± 7.34 2.62 ± 6.75 0.5 
Second troponin, ng/L 13.25 ± 11.26 12.28 ± 11.35 14.60 ± 11.17 0.3 
Involved vessel    0.1 
Anterior 12 (12%) 7 (11.2%) 5 (13.1%)  
Anteroseptal 7 (7%) 2 (3.2%) 5 (13.1%)  
Anterolateral 4 (4%) 4 (6.4%) 0 (0%)  
Extensive 3 (3%) 2 (3.2%) 1 (2.6%)  
Inferior 18 (18%) 11 (17.7%) 7 (18.4%)  
Inferior and right ventricule 5 (5%) 4 (6.4%) 1 (2.6%)  
Data in table are presented as Mean ± SD 
CK-MB: Creatine kinase-MB 
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Table 4. Comparing the Treatments Received during Hospitalization and the Post–discharge Complications between the Patients of the two Groups 
 Total, No. = 100 PCI groupm No. = 62 Thrombolytic group, No. = 38 P value* 
Frequency of medications prescribed     
Aspirin  98 (98%) 60 (96.7%) 38 (100%) 0.2 
Clopidogrel  97 (97%) 59 (95.1%) 38 (100%) 0.1 
Statins  88 (88%) 54 (87%) 34 (89.4%) 0.7 
ACEi 58 (58%) 32 (51.6%) 26 (81.2%) 0.09 
Beta–blocker 62 (62%) 35 (56.4%) 27 (71%) 0.1 
Recurrent ischemia 1 (1%) 0 (0%) 1 (2.6%) 0.1 
Recurrent myocardial infarction 2 (2%) 0 (0%) 2 (5.2%) 0.2 
Post–treatment stroke 4 (4%) 2 (3.2%) 2 (5.2%) 0.6 
Post–treatment gastrointestinal bleeding 0 (0%) 0 (0%) 0 (0%) – 
Death  14 (14%) 9 (14.5%) 5 (13.1%) 0.8 
Data in table are presented as No. (%) 
ACEi: Angiotensin-converting-enzyme inhibitor 
 
The frequency of post-treatment complications 
including recurrent ischemia, MI, and stroke did not 
differ between the groups (P > 0.05) (Table 4). There 
was no case of gastrointestinal bleeding after treatment. 
Of the 14 cases that died after six months, five belonged 
to the thrombolytic therapy group and nine to the PCI 
group (P = 0.8). Mean hospital stay was not different 
between the PCI and thrombolytic therapy groups (8.83 
± 7.98 vs. 9.68 ± 5.38 days, respectively) (P = 0.5). 
Discussion 
The present study compared the short- and long-term 
follow-up outcomes of elderly patients with STEMI 
receiving PCI (N = 62) or undergoing thrombolytic 
therapy (N = 38), based on their ischemic time. As the 
results indicated, the hospitalization duration, six-
month mortality rate, and post-treatment 
complications, including recurrent ischemia, MI, and 
stroke did not differ between the groups. These results 
indicated that PCI had no priority to the thrombolytic 
therapy in the studied patients. 
Studies comparing the mortality rate after PCI and 
thrombolytic therapy reported controversial results. 
Rymuza et al., reported higher mortality rates in 
hospitals with no access to PCI, compared to those 
performing PCI in the first 24-hour and showed reduced 
early and long-term mortality rate of patients >80 years 
old with STEMI [15]. de Boer et al., studied patients > 
75 years with acute MI and compared the mortality rates 
between PCI and streptokinase and rep orted 
significantly lower 30-day and 1-year mortality rate by 
PCI vs. streptokinase (9% vs. 29% and 13% vs. 44%, 
respectively) [16]. The results of the above mentioned 
studies on the elderly population [15, 16] were 
inconsistent with those of the current study, as they 
reported significant differences in mortality rate and 
post-treatment complications between the groups 
receiving PCI or thrombolytic medication. Also, a 
prospective observational cohort study on 26,205 
patients with STEMI reported lower mortality rates in 
primary PCI compared to in-hospital thrombolysis, 
after adjusting for age [11]. One of the potential reasons 
for the difference between the results of the current 
study and the above-mentioned research could be the 
employment of thrombolytic therapy, since some used 
streptokinase, while some others used fibrin-specific 
medications [10]. Another contributing factor could be 
the effect of age on patients’ outcomes, since older 
patients may have more underlying diseases, which in 
turn can increase mortality rate [17]; accordingly, 
studies including patients within different age groups 
could have different mortality rates following PCI or 
medication therapy. 
Contrary to the results of the above mentioned studies 
[10, 11, 15, 16] and consistent with the results of the 
current study, some other studies reported no difference 
between the mortality rates of patients receiving PCI or 
thrombolytic therapy. The study by Bueno et al., 
investigated patients > 70 years old with STEMI and 
comparison of six-month mortality rate between the 
ones receiving tissue plasminogen activator or primary 
PCI, performed at two different centers, showed that the 
six-month mortality rate of the PCI group was not 
different from that of the medication therapy group 
[18]. Another study also reported no difference in 30-
day mortality rate between patients with STEMI aged > 
75 years treated with tenecteplase, compared to the ones 
treated with PCI [19]. The results of both of these 
studies were consistent with those of the present study, 
reporting no difference between PCI and thrombolytic 
therapy in the studied patients. A similar study also 
indicated no difference in mortality rate between 
patients receiving PCI and reteplase [20]. 
An important aspect in the treatment outcome of 
patients with STEMI, which may only contribute to the 
developing countries, is the lack of appropriate 
emergency services to take the patients to the hospital in 
the shortest interval. According to evidence, time is 
considered as an important factor in treatment success 
rate of PCI and the interval between arrest and balloon 
are considered golden minutes [21]. As suggested, the 
beneficiary effect of fibrinolysis on reducing the 
mortality rate, as compared with PCI, diminishes per 10 
minutes’ time delay [22].In the current study, among 62 
elderly patients undergoing primary PCI, 14.5% died 
within six months, while in thrombolytic therapy group 
13.15% died within the same period; hence, the mean 
ischemic time was not significantly different between 
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the groups. These results suggested the 
inappropriateness of emergency care services, even in 
the capital of Iran, which should be considered by the 
policy makers. 
Other researchers suggested that even if PCI was not 
available at the admitted hospital, it is safe and feasible 
to transport the patient to a tertiary hospital with 
thrombolytic therapy facilities [23-25], which confirms 
the effectiveness of PCI. In the present study, the 
mortality rate of patients was lower than those of some 
previous studies in Iran and higher than those of some 
others performed worldwide. An epidemiologic study 
on 20,750 patients with acute MI reported a general 
mortality rate of 12.1%, while about 85% of deaths were 
related to patients with STEMI [26]. Another study also 
reported a mortality rate of 13.2% for MI, with 
significantly worse outcomes in patients with STEMI 
[27].The mortality rates reported in these studies, 
although similar to that of the thrombolytic group, 
cannot be compared with those of the current study, 
since they did not report the rates based on the type of 
MI (STEMI vs. non-STEMI) or the treatments 
received. Donyavi et al., reported a mortality rate of 
24.6% after acute MI in Iranian patients [28], which was 
higher than the mortality rates of both groups in the 
present study, although they did not separate the rates 
based on the type of disease. An important findings of 
these studies indicated that the socio-demographic 
characteristics of patients, type of MI, and the 
concomitant diseases played a fundamental role in the 
mortality rate [26-28], which could also attribute to the 
difference in the reported mortality rates. 
One of the limitations of the present study was the non-
random inclusion of patients into the study and 
selection of patients from one center, which decreased 
the generalizability of the results, although the study site 
was a tertiary center in the city center with high patient 
load. Furthermore, allocation of the patients into the 
study groups was not randomized, and the medical 
indications, ie ischemic time, should also be considered. 
Nonetheless, the results showed that patients were 
matched by demographic characteristics (such as age, 
gender, frequency of underling diseases, and smoking), 
as well as serum parameters. Thus, the groups were 
similar, although other confounders might not have 
been investigated in the present study. 
Conclusion 
According to the literature, different results were 
reported and the superiority of PCI over thrombolytic 
therapy was not confirmed in the current study. The 
results of comparison of two groups of patients > 65 
years with STEMI with similar baseline characteristics 
in the current study showed no differences in hospital 
stay, six-month mortality rate, and post-treatment 
complications, including recurrent ischemia, MI, and 
stroke between patients receiving PCI or thrombolytic 
medication. Since mortality rate and post-discharge 
complications depend on several factors, more studies 
are required to determine the differences between short- 
and long-term outcomes of patients from different age 
groups between the two treatments. 
Acknowledgements 
The authors wish to thank Shahid Beheshti University 
of Medical Science. 
Financial Disclosure 
The authors declared no conflicts of interest. 
References 
1. Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M. 
Global, regional, and national age-sex specific all-cause and 
cause-specific mortality for 240 causes of death, 1990-2013: a 
systematic analysis for the Global Burden of Disease Study 
2013. Lancet. 2015;385(9963):117-71. doi: 10.1016/S0140-
6736(14)61682-2 pmid: 25530442 
2. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett 
DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 
Update: A Report From the American Heart Association. 
Circulation. 2016;133(4):e38-360. doi: 10.1161/CIR.0000 
000000000350 pmid: 26673558 
3. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy 
A. Growing epidemic of coronary heart disease in low- and 
middle-income countries. Curr Probl Cardiol. 2010;35(2):72-
115. doi: 10.1016/j.cpcardiol.2009.10.002 pmid: 20109979 
4. Abubakar II, Tillmann T, Banerjee A. Global, regional, and 
national age-sex specific all-cause and cause-specific mortality 
for 240 causes of death, 1990-2013: a systematic analysis for 
the Global Burden of Disease Study 2013. Lancet. 
2015;385(9963):117-71. doi: 10.1016/S0140-6736(14)61 
682-2  
5. Talebizadeh N, Haghdoust AA, Mirzazadeh A. An 
epidemiological model (Markov Chain) of cardiovascular 
disease in Iran. Payesh. 2015;8(2):163-70.  
6. Task Force on the management of S T segment elevation acute 
myocardial infarction of the European Society of Cardiology, 
Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist 
C, et al. ESC Guidelines for the management of acute 
myocardial infarction in patients presenting with ST-segment 
elevation. Eur Heart J. 2012;33(20):2569-619. doi: 
10.1093/eurheartj/ehs215 pmid: 22922416 
7. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, 
Hand M, et al. ACC/AHA guidelines for the management of 
patients with ST-elevation myocardial infarction--executive 
summary. A report of the American College of 
Cardiology/American Heart Association Task Force on 
Practice Guidelines (Writing Committee to revise the 1999 
guidelines for the management of patients with acute 
myocardial infarction). J Am Coll Cardiol. 2004;44(3):671-
719. doi: 10.1016/j.jacc.2004.07.002 pmid: 15358045 
8. Medical Advisory S. Primary Angioplasty for the Treatment of 
Acute ST-Segment Elevated Myocardial Infarction: An 
Evidence-Based Analysis. Ont Health Technol Assess Ser. 
2004;4(10):1-65. pmid: 23074449 
9. Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, 
Frederick PD, et al. The volume of primary angioplasty 
procedures and survival after acute myocardial infarction. 
National Registry of Myocardial Infarction 2 Investigators. N 
Engl J Med. 2000;342(21):1573-80. doi: 10.1056/NEJM2000 
05253422106 pmid: 10824077 
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus 
intravenous thrombolytic therapy for acute myocardial 
infarction: a quantitative review of 23 randomised trials. 
Lancet. 2003;361(9351):13-20. doi: 10.1016/S0140-
6736(03)12113-7 pmid: 12517460 
International Journal of Cardiovascular Practice  Kazemi et al 
15 
11. Stenestrand U, Lindback J, Wallentin L, Registry R-H. Long-
term outcome of primary percutaneous coronary intervention 
vs prehospital and in-hospital thrombolysis for patients with 
ST-elevation myocardial infarction. JAMA. 
2006;296(14):1749-56. doi: 10.1001/jama.296.14.1749 
pmid: 17032988 
12. Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW, 
Chan L. Treatment of acute myocardial infarction and 30-day 
mortality among women and men. N Engl J Med. 
2000;343(1):8-15. doi: 10.1056/NEJM200007063430102 
pmid: 10882763 
13. Yaghoubi A, Tabrizi JS, Mirinazhad MM, Azami S, Naghavi-
Behzad M, Ghojazadeh M. Quality of life in cardiovascular 
patients in iran and factors affecting it: a systematic review. J 
Cardiovasc Thorac Res. 2012;4(4):95-101. doi: 
10.5681/jcvtr.2012.024 pmid: 24250995 
14. Pearson TA, Palaniappan LP, Artinian NT, Carnethon MR, 
Criqui MH, Daniels SR, et al. American Heart Association 
Guide for Improving Cardiovascular Health at the Community 
Level, 2013 update: a scientific statement for public health 
practitioners, healthcare providers, and health policy makers. 
Circulation. 2013;127(16):1730-53. doi: 10.1161/CIR.0b 
013e31828f8a94 pmid: 23519758 
15. Rymuza H, Kowalik I, Drzewiecki A, Krzyzanowski W, 
Olszewski M, Dabrowski R, et al. Successful primary coronary 
angioplasty improves early and long-term outcomes in ST 
segment elevation acute coronary syndromes in patients above 
80 years of age. Kardiol Pol. 2011;69(4):346-54. pmid: 
21523668 
16. de Boer MJ, Ottervanger JP, van 't Hof AW, Hoorntje JC, 
Suryapranata H, Zijlstra F, et al. Reperfusion therapy in elderly 
patients with acute myocardial infarction: a randomized 
comparison of primary angioplasty and thrombolytic therapy. 
J Am Coll Cardiol. 2002;39(11):1723-8. doi: 10.1016/S0735-
1097(02)01878-8 pmid: 12039482 
17. Ciszewski A, Karcz M, Kepka C, Bekta P, Ksiezycka E, 
Przyluski J, et al. Primary angioplasty in patients > or = 75 years 
old with ST-elevation myocardial infarction - one-year follow-
up results. Kardiol Pol. 2008;66(8):828-33; discussion 34-6. 
pmid: 18803134 
18. Bueno H, Betriu A, Heras M, Alonso JJ, Cequier A, García EJ, 
et al. Primary angioplasty vs. fibrinolysis in very old patients 
with acute myocardial infarction: TRIANA (TRatamiento del 
Infarto Agudo de miocardio eN Ancianos) randomized trial 
and pooled analysis with previous studies. European heart 
journal. 2010;32(1):51-60. doi: 10.1093/eurheartj/ehq375  
19. Goldenberg I, Matetzky S, Halkin A, Roth A, Di Segni E, 
Freimark D, et al. Primary angioplasty with routine stenting 
compared with thrombolytic therapy in elderly patients with 
acute myocardial infarction. Am Heart J. 2003;145(5):862-7. 
doi: 10.1016/S0002-8703(02)94709-5 pmid: 12766745 
20. Alimohammadzadeh K, Sadeghi R, Maher A, Kazemi MK. 
Short-term Cost-effectiveness of Reteplase versus Primary 
Percutaneous Coronary Intervention in Patients with Acute 
STEMI a Tertiary Hospital in Iran. Int J Cardiovasc Pract. 
2017;2(3):65-9. doi: 10.21859/ijcp-020305  
21. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. 
Time delay to treatment and mortality in primary angioplasty 
for acute myocardial infarction: every minute of delay counts. 
Circulation. 2004;109(10):1223-5. doi: 
10.1161/01.CIR.0000121424.76486.20 pmid: 15007008 
22. De Luca G, Cassetti E, Marino P. Percutaneous coronary 
intervention-related time delay, patient's risk profile, and 
survival benefits of primary angioplasty vs lytic therapy in ST-
segment elevation myocardial infarction. Am J Emerg Med. 
2009;27(6):712-9. doi: 10.1016/j.ajem.2008.04.026 pmid: 
19751630 
23. Otsuka M, Yamamoto H, Okimoto T, Dohi Y, Mito S, Gomyo 
Y, et al. Long-term effects of quinapril with high affinity for 
tissue angiotensin-converting enzyme after coronary 
intervention in Japanese. Am Heart J. 2004;147(4):662-8. doi: 
10.1016/j.ahj.2003.10.037 pmid: 15077082 
24. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. 
Angiotensin-converting enzyme inhibitors in coronary artery 
disease and preserved left ventricular systolic function: a 
systematic review and meta-analysis of randomized controlled 
trials. J Am Coll Cardiol. 2006;47(8):1576-83. doi: 
10.1016/j.jacc.2005.11.073 pmid: 16630993 
25. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, 
Suryapranata H. Multicentre randomized trial comparing 
transport to primary angioplasty vs immediate thrombolysis vs 
combined strategy for patients with acute myocardial 
infarction presenting to a community hospital without a 
catheterization laboratory. The PRAGUE study. Eur Heart J. 
2000;21(10):823-31. doi: 10.1053/euhj.1999.1993 pmid: 
10781354 
26. Ahmadi A, Soori H, Mehrabi Y, Etemad K, Khaledifar A. 
Epidemiological pattern of myocardial infarction and 
modelling risk factors relevant to in-hospital mortality: the first 
results from the Iranian Myocardial Infarction Registry. 
Kardiol Pol. 2015;73(6):451-7. doi: 10.5603/KP.a2014.0230 
pmid: 25428813 
27. Ahmadi A, Soori H, Sajjadi H. Modeling of in hospital 
mortality determinants in myocardial infarction patients, with 
and without type 2 diabetes, undergoing pharmaco-invasive 
strategy: the first national report using two approaches in Iran. 
Diabetes Res Clin Pract. 2015;108(2):216-22. doi: 
10.1016/j.diabres.2015.02.018 pmid: 25771308 
28. Donyavi T, Naieni KH, Nedjat S, Vahdaninia M, Najafi M, 
Montazeri A. Socioeconomic status and mortality after acute 
myocardial infarction: a study from Iran. Int J Equity Health. 
2011;10(1):9. doi: 10.1186/1475-9276-10-9 pmid: 21299888
 
 
